Juno Research   Report issue

For profit Phase 2
Founded: Houston TX United States (2004)

Organization Overview

First Clinical Trial
2013
NCT01819272
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Juno Research, LLC - Houston | Juno Research, LLC - Katy

Active Ingredients

Drugs in Phase 2 Trials (1)

sitagliptin (januvia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1